Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, B-Cell, Marginal Zone 14Lymphoma, Mantle-Cell 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma 3Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Recurrence 1Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 240Rituximab 187fludarabine phosphate 129Etoposide 110Peripheral Blood Stem Cell Transplantation 108Mycophenolic Acid 94Filgrastim 91Melphalan 90Whole-Body Irradiation 88fludarabine 80Busulfan 80Tacrolimus 71Cytarabine 66Cyclosporine 66Radiotherapy 62Methotrexate 53Antilymphocyte Serum 53Granulocyte Colony-Stimulating Factor 51Vincristine 49Carmustine 48Doxorubicin 41Prednisone 37Thiotepa 33Bendamustine Hydrochloride 32Bortezomib 30Methylprednisolone 29Dexamethasone 28Stem Cell Transplantation 27thymoglobulin 26ibritumomab tiuxetan 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Non-Hodgkin × orelabrutinib × Clear all
NCT05021770 2021-08-26

Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma

Sun Yat-sen University

Phase 1/2 Unknown
29 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡